Abstract
Bisphosphonates are standard treatment for cancer-induced bone disease, a common feature of many advanced malignancies. Traditionally used to inhibit bone turnover and reduce the risk of skeletal-related events, there is now increasing pre-clinical evidence that these agents may also affect tumour burden and disease progression. In particular, combining bisphosphonates with chemotherapeutic agents has been demonstrated to cause substantially increased anti-tumour effects compared to giving the single agents. Clinical studies are in progress to determine whether adding bisphosphonates to standard anti-cancer therapy results in improved outcome for patients. Here we give an overview of the key pre-clinical studies of anti-tumour effects of bisphosphonates, alone and in combination with other agents, and introduce some of the ongoing clinical trials that aim to determine the clinical relevance of bisphosphonates in combination therapy.
Keywords: Zoledronic acid, metastatic bone disease, synergy, bone, Combined Therapies, Bone Disease, Bisphosphonates, advanced malignancies, chemotherapeutic agents, synergy, bone, kidney, prostate, lytic and sclerotic elements, anti-scaling agents, Paget's disease, cholesterol, post-translational modification, osteoclast activity, anti-cancer agents, umour cell apoptosis, MB-231, MCF-7, Hs 578T, alendronate, ibandronate, pamidronate, risedronate, bovine cortical bone slices, cervical intraepithelial neoplasia, lung cancer cells, tumour vascularisation, anti-tumourigenic, osteolytic lesions, non-bone metastases, prostate cancer, zole-dronic acid, T-cell leukemia, regulating tumour growth, COMBINATION THERAPY, invasive cancer, doxorubicin, chemotherapeutic agent, prostate cancer cell lines, mouse breast cancer, intra-cardiac injection, osteolytic bone disease, anatomical, invasive breast cancer, angiogenesis, neo-adjuvant anthracycline, antitumour effects
Current Pharmaceutical Design
Title: Combined Therapies of Bone Disease with Bisphosphonates
Volume: 16 Issue: 27
Author(s): S. P. Syddall, P. D. Ottewell and I. Holen
Affiliation:
Keywords: Zoledronic acid, metastatic bone disease, synergy, bone, Combined Therapies, Bone Disease, Bisphosphonates, advanced malignancies, chemotherapeutic agents, synergy, bone, kidney, prostate, lytic and sclerotic elements, anti-scaling agents, Paget's disease, cholesterol, post-translational modification, osteoclast activity, anti-cancer agents, umour cell apoptosis, MB-231, MCF-7, Hs 578T, alendronate, ibandronate, pamidronate, risedronate, bovine cortical bone slices, cervical intraepithelial neoplasia, lung cancer cells, tumour vascularisation, anti-tumourigenic, osteolytic lesions, non-bone metastases, prostate cancer, zole-dronic acid, T-cell leukemia, regulating tumour growth, COMBINATION THERAPY, invasive cancer, doxorubicin, chemotherapeutic agent, prostate cancer cell lines, mouse breast cancer, intra-cardiac injection, osteolytic bone disease, anatomical, invasive breast cancer, angiogenesis, neo-adjuvant anthracycline, antitumour effects
Abstract: Bisphosphonates are standard treatment for cancer-induced bone disease, a common feature of many advanced malignancies. Traditionally used to inhibit bone turnover and reduce the risk of skeletal-related events, there is now increasing pre-clinical evidence that these agents may also affect tumour burden and disease progression. In particular, combining bisphosphonates with chemotherapeutic agents has been demonstrated to cause substantially increased anti-tumour effects compared to giving the single agents. Clinical studies are in progress to determine whether adding bisphosphonates to standard anti-cancer therapy results in improved outcome for patients. Here we give an overview of the key pre-clinical studies of anti-tumour effects of bisphosphonates, alone and in combination with other agents, and introduce some of the ongoing clinical trials that aim to determine the clinical relevance of bisphosphonates in combination therapy.
Export Options
About this article
Cite this article as:
P. Syddall S., D. Ottewell P. and Holen I., Combined Therapies of Bone Disease with Bisphosphonates, Current Pharmaceutical Design 2010; 16 (27) . https://dx.doi.org/10.2174/138161210793563590
DOI https://dx.doi.org/10.2174/138161210793563590 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radionuclides Used in Nuclear Medicine Therapy – From Production to Dosimetry
Current Medical Imaging A Systematic Review of Selected Musculoskeletal Late Effects in Survivors of Childhood Cancer
Current Pediatric Reviews Gene Therapy in In Vivo Isolated Perfusion Models
Current Gene Therapy MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) Merlin, a “Magic” Linker Between the Extracellular Cues and Intracellular Signaling Pathways that Regulate Cell Motility, Proliferation, and Survival
Current Protein & Peptide Science Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry Glycoxidation and Wound Healing in Diabetes: An Interesting Relationship
Current Diabetes Reviews Apoptosis-Inducing Activity of the S100A8/A9 Heterodimer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers Chemical Biology of mGlu4 Receptor Activation: Dogmas, Challenges, Strategies and Opportunities
Current Topics in Medicinal Chemistry HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting
Current Pharmaceutical Design Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry Flavonoids Active Against Osteosarcoma: A Review of the Molecular Mechanisms Involved
Current Pharmaceutical Design Substrates for Improved Live-Cell Fluorescence Labeling of SNAP-tag
Current Pharmaceutical Design Influence of the Bystander Effect on HSV-tk / GCV Gene Therapy. A Review.
Current Gene Therapy Toxicity Mechanism of Gadolinium Oxide Nanoparticles and Gadolinium Ions in Human Breast Cancer Cells
Current Drug Metabolism ICE Regimen for Relapsed/Refractory Bone and Soft Tissue Sarcomas in Children
Reviews on Recent Clinical Trials Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine Rho GTPases: Promising Cellular Targets for Novel Anticancer Drugs
Current Cancer Drug Targets